NGNE

SEC source: 0001209191-21-041814 · doc4.xml · nonDerivative · entry 1

Walkey Carl · CIK 0001843189 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,352,489

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

SEC source: 0001209191-21-039819 · doc4.xml · nonDerivative · entry 1

Walkey Carl · CIK 0001843189 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,353,089

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $10.81 and the highest price at which shares were sold was $11.00. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

SEC source: 0001209191-21-039223 · doc4.xml · nonDerivative · entry 1

Walkey Carl · CIK 0001843189 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,353,739

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

SEC source: 0001209191-21-038696 · doc4.xml · nonDerivative · entry 1

Walkey Carl · CIK 0001843189 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,354,339

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

SEC source: 0001209191-21-038690 · doc4.xml · nonDerivative · entry 2

DRACHMAN JONATHAN G · CIK 0001588467 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,248,686

F2 · price: Represents the weighted average purchase price. The lowest price at which shares were purchased was $9.56 and the highest price at which shares were purchased was $9.62.

SEC source: 0001209191-21-038690 · doc4.xml · nonDerivative · entry 1

DRACHMAN JONATHAN G · CIK 0001588467 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,238,686

F1 · price: Represents the weighted average purchase price. The lowest price at which shares were purchased was $9.38 and the highest price at which shares were purchased was $9.51. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.

SEC source: 0001209191-21-036057 · doc4.xml · nonDerivative · entry 1

Walkey Carl · CIK 0001843189 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,354,939

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

SEC source: 0001209191-21-035020 · doc4.xml · nonDerivative · entry 1

Walkey Carl · CIK 0001843189 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,355,539

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2 · balance_after: Includes 1,377 shares of Common Stock acquired on May 14, 2021 pursuant to the Issuer's employee stock purchase plan.

SEC source: 0001209191-21-032244 · doc4.xml · nonDerivative · entry 1

Walkey Carl · CIK 0001843189 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,354,762

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

SEC source: 0001638599-21-000464 · doc4_7218.xml · derivative · entry 1

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2031-05-10

F1 · derivative.exercise_date: 25,000 non-qualified stock options ("Stock Options") exercisable solely into common stock of Neoleukin Therapeutics, Inc. (the "Issuer") were granted under the Issuer's 2014 Equity Incentive Plan to M. Cantey Boyd, a full-time employee of Baker Bros. Advisors LP (the "Adviser") in her capacity as a director of the Issuer. The Stock Options with a strike price of $11.40 vest in 12 equal monthly installments beginning on June 11, 2021, subject to M. Cantey Boyd's continued service on the board of directors of the Issuer (the "Board") and expire on May 10, 2031. M. Cantey Boyd serves on the Board as a representative of Baker Brothers Life Sciences, L.P. ("Life Sciences") and 667, L.P. ("667", and together with Life Sciences, the "Funds").

F1 · ownership.nature: 25,000 non-qualified stock options ("Stock Options") exercisable solely into common stock of Neoleukin Therapeutics, Inc. (the "Issuer") were granted under the Issuer's 2014 Equity Incentive Plan to M. Cantey Boyd, a full-time employee of Baker Bros. Advisors LP (the "Adviser") in her capacity as a director of the Issuer. The Stock Options with a strike price of $11.40 vest in 12 equal monthly installments beginning on June 11, 2021, subject to M. Cantey Boyd's continued service on the board of directors of the Issuer (the "Board") and expire on May 10, 2031. M. Cantey Boyd serves on the Board as a representative of Baker Brothers Life Sciences, L.P. ("Life Sciences") and 667, L.P. ("667", and together with Life Sciences, the "Funds").

F2 · ownership.nature: The policies of the Funds and the Adviser do not permit full-time employees of the Adviser or managing members of the Adviser GP (as defined below) to receive compensation for serving as a director of the Issuer. The Funds are entitled to receive all of the pecuniary interest in the securities issued. The Funds each own an indirect proportionate pecuniary interest in the Stock Options. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options (i.e. no direct pecuniary interest).

F3 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. The Adviser has investment and dispositive power over the Stock Options and any common stock of the Issuer received as a result of the exercise of Stock Options.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001209191-21-032400 · doc4.xml · derivative · entry 1

Lavelle Erin M. · CIK 0001813250 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2031-05-10

F1 · derivative.exercise_date: The option vests as to 1/12 of the total shares monthly beginning June 11, 2021 until the option is fully vested on May 11, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-21-032401 · doc4.xml · derivative · entry 1

Noonberg Sarah B. · CIK 0001706301 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2031-05-10

F1 · derivative.exercise_date: The option vests as to 1/12 of the total shares monthly beginning June 11, 2021 until the option is fully vested on May 11, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-21-032397 · doc4.xml · derivative · entry 1

Babler Martin · CIK 0001435618 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2031-05-10

F1 · derivative.exercise_date: The option vests as to 1/12 of the total shares monthly beginning June 11, 2021 until the option is fully vested on May 11, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-21-032406 · doc4.xml · derivative · entry 1

Williams Lewis T · CIK 0001475714 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2031-05-10

F1 · derivative.exercise_date: The option vests as to 1/12 of the total shares monthly beginning June 11, 2021 until the option is fully vested on May 11, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-21-032404 · doc4.xml · derivative · entry 1

SIMPSON TODD E · CIK 0001216477 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2031-05-10

F1 · derivative.exercise_date: The option vests as to 1/12 of the total shares monthly beginning June 11, 2021 until the option is fully vested on May 11, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-21-030654 · doc4.xml · nonDerivative · entry 1

Walkey Carl · CIK 0001843189 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,355,962

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

SEC source: 0001209191-21-029907 · doc4.xml · derivative · entry 2

Patel Priti · CIK 0001859997 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 475,000

Underlying: Common Stock · 475,000 shares

Expires 2031-04-30

F4 · derivative.exercise_date: The option vests as to 1/4 of the total shares on April 30, 2022, and then 1/48 of the total shares will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-21-029907 · doc4.xml · derivative · entry 1

Patel Priti · CIK 0001859997 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.

F2 · derivative.exercise_date: The RSUs will vest as to 1/2 of the total number of shares underlying the award on each of April 30, 2022 and April 30, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F3 · derivative.expiration_date: The RSUs do not expire; these securities either vest and settle or are canceled prior to the vesting date.

SEC source: 0001209191-21-029342 · doc4.xml · nonDerivative · entry 1

Walkey Carl · CIK 0001843189 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,357,162

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $12.44 and the highest price at which shares were sold was $13.00. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

SEC source: 0001209191-21-028727 · doc4.xml · nonDerivative · entry 1

Walkey Carl · CIK 0001843189 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,359,562

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

SEC source: 0001209191-21-027971 · doc4.xml · nonDerivative · entry 1

Walkey Carl · CIK 0001843189 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,360,162

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $11.97 and the highest price at which shares were sold was $12.00. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

SEC source: 0001209191-21-027050 · doc4.xml · nonDerivative · entry 1

Walkey Carl · CIK 0001843189 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,361,962

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

SEC source: 0001209191-21-026153 · doc4.xml · nonDerivative · entry 1

Walkey Carl · CIK 0001843189 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,363,762

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

SEC source: 0001209191-21-025767 · doc4.xml · nonDerivative · entry 1

Walkey Carl · CIK 0001843189 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,365,562

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

SEC source: 0001209191-21-024707 · doc4.xml · nonDerivative · entry 1

Walkey Carl · CIK 0001843189 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,366,162

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $11.94 and the highest price at which shares were sold was $12.00. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

SEC source: 0001209191-21-022929 · doc4.xml · nonDerivative · entry 2

Walkey Carl · CIK 0001843189 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,367,962

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $11.93 and the highest price at which shares were sold was $12.00. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

SEC source: 0001209191-21-022929 · doc4.xml · nonDerivative · entry 1

Walkey Carl · CIK 0001843189 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,369,762

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

SEC source: 0001209191-21-021946 · doc4.xml · nonDerivative · entry 1

Walkey Carl · CIK 0001843189 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,370,362

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

SEC source: 0001209191-21-021943 · doc4.xml · nonDerivative · entry 2

Ho Robert · CIK 0001806254 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,503

F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

SEC source: 0001209191-21-021943 · doc4.xml · derivative · entry 3

Ho Robert · CIK 0001806254 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 25,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.

F3 · derivative.exercise_date: The RSUs will vest as to 1/3 of the total number of shares underlying the award on each of March 16, 2021, March 16, 2022 and March 16, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F4 · derivative.expiration_date: The RSUs do not expire; these securities either vest and settle or are canceled prior to the vesting date.

SEC source: 0001209191-21-021943 · doc4.xml · nonDerivative · entry 1

Ho Robert · CIK 0001806254 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-019776 · doc4.xml · nonDerivative · entry 1

Walkey Carl · CIK 0001843189 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,371,562

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $11.95 and the highest price at which shares were sold was $12.00. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

SEC source: 0001209191-21-017994 · doc4.xml · nonDerivative · entry 1

Walkey Carl · CIK 0001843189 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,373,362

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $11.80 and the highest price at which shares were sold was $12.00. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

SEC source: 0001209191-21-014513 · doc4.xml · nonDerivative · entry 2

Walkey Carl · CIK 0001843189 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,375,162

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

SEC source: 0001209191-21-014513 · doc4.xml · nonDerivative · entry 1

Walkey Carl · CIK 0001843189 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,375,762

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

SEC source: 0001209191-21-011834 · doc4.xml · nonDerivative · entry 1

Walkey Carl · CIK 0001843189 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,377,562

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $12.62 and the highest price at which shares were sold was $13.00. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

SEC source: 0001209191-21-010148 · doc4.xml · nonDerivative · entry 1

Walkey Carl · CIK 0001843189 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,379,962

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

SEC source: 0001209191-21-008839 · doc4.xml · nonDerivative · entry 1

Walkey Carl · CIK 0001843189 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,382,962

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

SEC source: 0001209191-21-008129 · doc4.xml · nonDerivative · entry 1

Walkey Carl · CIK 0001843189 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,383,562

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

SEC source: 0001209191-21-006730 · doc4.xml · derivative · entry 1

Walkey Carl · CIK 0001843189 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2031-01-30

F1 · derivative.exercise_date: The option vests as to 1/4 of the total shares on January 30, 2022, and then 1/48 of the total shares will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-20-055395 · doc4.xml · derivative · entry 1

Vance Holly · CIK 0001827307 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 220,000

Underlying: Common Stock · 220,000 shares

Expires 2030-10-19

F1 · derivative.exercise_date: The option vests as to 1/4 of the total shares on October 19, 2021, and then 1/48 of the total shares will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-20-049966 · doc4.xml · derivative · entry 1

Babler Martin · CIK 0001435618 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2030-09-08

F1 · derivative.exercise_date: The option vests as to 1/3 of the total shares on each of September 8, 2021, September 8, 2022 and September 8, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-20-046342 · doc4.xml · derivative · entry 1

Ho Robert · CIK 0001806254 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2030-08-10

F1 · derivative.exercise_date: The option vests as to 1/4 of the total shares on August 10, 2021, and then 1/48 of the total shares will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-20-046339 · doc4.xml · derivative · entry 1

DRACHMAN JONATHAN G · CIK 0001588467 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 420,000

Underlying: Common Stock · 420,000 shares

Expires 2030-08-10

F1 · derivative.exercise_date: The option vests as to 1/4 of the total shares on August 10, 2021, and then 1/48 of the total shares will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001638599-20-000993 · doc4_6973.xml · derivative · entry 6

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 10,283,888

Underlying: Common Stock · 518,555 shares

Expires not disclosed

F3 · derivative.exercise_price: 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") purchased 29,640 and 394,360 shares of Common Stock, respectively, for $15.25 per share and 38,974 and 518,555 warrants to purchase Common Stock at an exercise price of $0.000001 per share with no expiration date ("Pre-Funded Warrants"), respectively, for $15.249999 in an underwritten public offering (the "Offering") that closed on July 7, 2020. The Pre-Funded warrants are exercisable immediately on a 1-for-1 basis into Common Stock to the extent that after giving effect to such exercise the holders thereof and their affiliates would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of Common Stock (the "Maximum Percentage").

F3 · shares: 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") purchased 29,640 and 394,360 shares of Common Stock, respectively, for $15.25 per share and 38,974 and 518,555 warrants to purchase Common Stock at an exercise price of $0.000001 per share with no expiration date ("Pre-Funded Warrants"), respectively, for $15.249999 in an underwritten public offering (the "Offering") that closed on July 7, 2020. The Pre-Funded warrants are exercisable immediately on a 1-for-1 basis into Common Stock to the extent that after giving effect to such exercise the holders thereof and their affiliates would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of Common Stock (the "Maximum Percentage").

F3 · price: 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") purchased 29,640 and 394,360 shares of Common Stock, respectively, for $15.25 per share and 38,974 and 518,555 warrants to purchase Common Stock at an exercise price of $0.000001 per share with no expiration date ("Pre-Funded Warrants"), respectively, for $15.249999 in an underwritten public offering (the "Offering") that closed on July 7, 2020. The Pre-Funded warrants are exercisable immediately on a 1-for-1 basis into Common Stock to the extent that after giving effect to such exercise the holders thereof and their affiliates would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of Common Stock (the "Maximum Percentage").

F3 · derivative.exercise_date: 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") purchased 29,640 and 394,360 shares of Common Stock, respectively, for $15.25 per share and 38,974 and 518,555 warrants to purchase Common Stock at an exercise price of $0.000001 per share with no expiration date ("Pre-Funded Warrants"), respectively, for $15.249999 in an underwritten public offering (the "Offering") that closed on July 7, 2020. The Pre-Funded warrants are exercisable immediately on a 1-for-1 basis into Common Stock to the extent that after giving effect to such exercise the holders thereof and their affiliates would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of Common Stock (the "Maximum Percentage").

F3 · derivative.expiration_date: 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") purchased 29,640 and 394,360 shares of Common Stock, respectively, for $15.25 per share and 38,974 and 518,555 warrants to purchase Common Stock at an exercise price of $0.000001 per share with no expiration date ("Pre-Funded Warrants"), respectively, for $15.249999 in an underwritten public offering (the "Offering") that closed on July 7, 2020. The Pre-Funded warrants are exercisable immediately on a 1-for-1 basis into Common Stock to the extent that after giving effect to such exercise the holders thereof and their affiliates would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of Common Stock (the "Maximum Percentage").

F5 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital L.P. and (ii) Life Sciences, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and Pre-Funded Warrants in column 9 of Table II directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

F6 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F7 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001638599-20-000993 · doc4_6973.xml · derivative · entry 5

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,199,122

Underlying: Common Stock · 38,974 shares

Expires not disclosed

F3 · derivative.exercise_price: 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") purchased 29,640 and 394,360 shares of Common Stock, respectively, for $15.25 per share and 38,974 and 518,555 warrants to purchase Common Stock at an exercise price of $0.000001 per share with no expiration date ("Pre-Funded Warrants"), respectively, for $15.249999 in an underwritten public offering (the "Offering") that closed on July 7, 2020. The Pre-Funded warrants are exercisable immediately on a 1-for-1 basis into Common Stock to the extent that after giving effect to such exercise the holders thereof and their affiliates would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of Common Stock (the "Maximum Percentage").

F3 · shares: 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") purchased 29,640 and 394,360 shares of Common Stock, respectively, for $15.25 per share and 38,974 and 518,555 warrants to purchase Common Stock at an exercise price of $0.000001 per share with no expiration date ("Pre-Funded Warrants"), respectively, for $15.249999 in an underwritten public offering (the "Offering") that closed on July 7, 2020. The Pre-Funded warrants are exercisable immediately on a 1-for-1 basis into Common Stock to the extent that after giving effect to such exercise the holders thereof and their affiliates would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of Common Stock (the "Maximum Percentage").

F3 · price: 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") purchased 29,640 and 394,360 shares of Common Stock, respectively, for $15.25 per share and 38,974 and 518,555 warrants to purchase Common Stock at an exercise price of $0.000001 per share with no expiration date ("Pre-Funded Warrants"), respectively, for $15.249999 in an underwritten public offering (the "Offering") that closed on July 7, 2020. The Pre-Funded warrants are exercisable immediately on a 1-for-1 basis into Common Stock to the extent that after giving effect to such exercise the holders thereof and their affiliates would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of Common Stock (the "Maximum Percentage").

F3 · derivative.exercise_date: 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") purchased 29,640 and 394,360 shares of Common Stock, respectively, for $15.25 per share and 38,974 and 518,555 warrants to purchase Common Stock at an exercise price of $0.000001 per share with no expiration date ("Pre-Funded Warrants"), respectively, for $15.249999 in an underwritten public offering (the "Offering") that closed on July 7, 2020. The Pre-Funded warrants are exercisable immediately on a 1-for-1 basis into Common Stock to the extent that after giving effect to such exercise the holders thereof and their affiliates would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of Common Stock (the "Maximum Percentage").

F3 · derivative.expiration_date: 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") purchased 29,640 and 394,360 shares of Common Stock, respectively, for $15.25 per share and 38,974 and 518,555 warrants to purchase Common Stock at an exercise price of $0.000001 per share with no expiration date ("Pre-Funded Warrants"), respectively, for $15.249999 in an underwritten public offering (the "Offering") that closed on July 7, 2020. The Pre-Funded warrants are exercisable immediately on a 1-for-1 basis into Common Stock to the extent that after giving effect to such exercise the holders thereof and their affiliates would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of Common Stock (the "Maximum Percentage").

F4 · ownership.nature: After giving effect to the transaction and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the Pre-Funded Warrants reported column 9 of Table II directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F6 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F7 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001638599-20-000993 · doc4_6973.xml · nonDerivative · entry 4

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,501,691

F3 · shares: 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") purchased 29,640 and 394,360 shares of Common Stock, respectively, for $15.25 per share and 38,974 and 518,555 warrants to purchase Common Stock at an exercise price of $0.000001 per share with no expiration date ("Pre-Funded Warrants"), respectively, for $15.249999 in an underwritten public offering (the "Offering") that closed on July 7, 2020. The Pre-Funded warrants are exercisable immediately on a 1-for-1 basis into Common Stock to the extent that after giving effect to such exercise the holders thereof and their affiliates would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of Common Stock (the "Maximum Percentage").

F3 · price: 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") purchased 29,640 and 394,360 shares of Common Stock, respectively, for $15.25 per share and 38,974 and 518,555 warrants to purchase Common Stock at an exercise price of $0.000001 per share with no expiration date ("Pre-Funded Warrants"), respectively, for $15.249999 in an underwritten public offering (the "Offering") that closed on July 7, 2020. The Pre-Funded warrants are exercisable immediately on a 1-for-1 basis into Common Stock to the extent that after giving effect to such exercise the holders thereof and their affiliates would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of Common Stock (the "Maximum Percentage").

F5 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital L.P. and (ii) Life Sciences, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and Pre-Funded Warrants in column 9 of Table II directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

F6 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F7 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001638599-20-000993 · doc4_6973.xml · nonDerivative · entry 3

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 320,049

F3 · shares: 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") purchased 29,640 and 394,360 shares of Common Stock, respectively, for $15.25 per share and 38,974 and 518,555 warrants to purchase Common Stock at an exercise price of $0.000001 per share with no expiration date ("Pre-Funded Warrants"), respectively, for $15.249999 in an underwritten public offering (the "Offering") that closed on July 7, 2020. The Pre-Funded warrants are exercisable immediately on a 1-for-1 basis into Common Stock to the extent that after giving effect to such exercise the holders thereof and their affiliates would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of Common Stock (the "Maximum Percentage").

F3 · price: 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") purchased 29,640 and 394,360 shares of Common Stock, respectively, for $15.25 per share and 38,974 and 518,555 warrants to purchase Common Stock at an exercise price of $0.000001 per share with no expiration date ("Pre-Funded Warrants"), respectively, for $15.249999 in an underwritten public offering (the "Offering") that closed on July 7, 2020. The Pre-Funded warrants are exercisable immediately on a 1-for-1 basis into Common Stock to the extent that after giving effect to such exercise the holders thereof and their affiliates would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of Common Stock (the "Maximum Percentage").

F4 · ownership.nature: After giving effect to the transaction and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the Pre-Funded Warrants reported column 9 of Table II directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F6 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F7 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001209191-20-033543 · doc4.xml · derivative · entry 1

Lavelle Erin M. · CIK 0001813250 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2030-06-01

F1 · derivative.exercise_date: The option vests as to 1/3 of the total shares on each of June 1, 2021, June 1, 2022 and June 1, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001638599-20-000417 · doc4_6658.xml · derivative · entry 1

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2030-05-04

F1 · derivative.exercise_date: 25,000 non-qualified stock options ("Stock Options") exercisable solely into common stock of Neoleukin Therapeutics, Inc. (the "Issuer") were granted under the Issuer's 2014 Equity Incentive Plan to M. Cantey Boyd, a full-time employee of Baker Bros. Advisors LP (the "Adviser") in her capacity as a director of the Issuer. The Stock Options with a strike price of $12.84 vest in 12 equal monthly installments beginning on June 5, 2020 and expire on May 4, 2030. M. Cantey Boyd serves on the board of directors of the Issuer (the "Board") as a representative of Baker Brothers Life Sciences, L.P. ("Life Sciences") and 667, L.P. ("667", and together with Life Sciences, the "Funds").

F1 · ownership.nature: 25,000 non-qualified stock options ("Stock Options") exercisable solely into common stock of Neoleukin Therapeutics, Inc. (the "Issuer") were granted under the Issuer's 2014 Equity Incentive Plan to M. Cantey Boyd, a full-time employee of Baker Bros. Advisors LP (the "Adviser") in her capacity as a director of the Issuer. The Stock Options with a strike price of $12.84 vest in 12 equal monthly installments beginning on June 5, 2020 and expire on May 4, 2030. M. Cantey Boyd serves on the board of directors of the Issuer (the "Board") as a representative of Baker Brothers Life Sciences, L.P. ("Life Sciences") and 667, L.P. ("667", and together with Life Sciences, the "Funds").

F2 · ownership.nature: The policies of the Funds and the Adviser does not permit full-time employees of the Adviser or managing members of the Adviser GP (as defined below) to receive compensation for serving as a director of the Issuer. The Funds are entitled to receive all the pecuniary interest in the securities issued. The Funds each own an indirect proportionate pecuniary interest in the Stock Options. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options (i.e. no direct pecuniary interest).

F3 · ownership.nature: The Adviser serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. The Adviser has investment and dispositive power over the Stock Options and any common stock of the Issuer received as a result of the exercise of Stock Options.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.